NL300746I2 - - Google Patents

Download PDF

Info

Publication number
NL300746I2
NL300746I2 NL300746C NL300746C NL300746I2 NL 300746 I2 NL300746 I2 NL 300746I2 NL 300746 C NL300746 C NL 300746C NL 300746 C NL300746 C NL 300746C NL 300746 I2 NL300746 I2 NL 300746I2
Authority
NL
Netherlands
Application number
NL300746C
Other versions
NL300746I1 (nl
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300746(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NL300746I2 publication Critical patent/NL300746I2/nl
Publication of NL300746I1 publication Critical patent/NL300746I1/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
NL300746C 2002-04-16 2015-06-29 NL300746I1 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16
PCT/US2003/011510 WO2003089428A1 (en) 2002-04-16 2003-04-14 Tricyclic thrombin receptor antagonists

Publications (2)

Publication Number Publication Date
NL300746I2 true NL300746I2 (nl) 2016-01-21
NL300746I1 NL300746I1 (nl) 2016-01-21

Family

ID=29250954

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300746C NL300746I1 (nl) 2002-04-16 2015-06-29

Country Status (34)

Country Link
US (3) US7304078B2 (nl)
EP (5) EP1860106B1 (nl)
JP (2) JP4558331B2 (nl)
KR (1) KR101026929B1 (nl)
CN (1) CN1659162B (nl)
AR (1) AR039570A1 (nl)
AT (3) ATE455774T1 (nl)
AU (1) AU2003221932B2 (nl)
BR (1) BRPI0309309B8 (nl)
CA (1) CA2482858C (nl)
CY (3) CY1107184T1 (nl)
DE (3) DE60331114D1 (nl)
DK (2) DK1495018T3 (nl)
EC (1) ECSP045368A (nl)
ES (3) ES2338171T3 (nl)
FR (1) FR15C0047I2 (nl)
HK (3) HK1070887A1 (nl)
IL (1) IL164585A (nl)
LT (1) LTC1495018I2 (nl)
LU (1) LU92759I2 (nl)
MX (1) MXPA04010308A (nl)
MY (1) MY144040A (nl)
NL (1) NL300746I1 (nl)
NO (2) NO330500B1 (nl)
NZ (2) NZ535880A (nl)
PE (1) PE20040412A1 (nl)
PL (1) PL214718B1 (nl)
PT (2) PT2065384E (nl)
RU (2) RU2329264C9 (nl)
SG (1) SG164279A1 (nl)
SI (2) SI1495018T1 (nl)
TW (1) TWI343919B (nl)
WO (1) WO2003089428A1 (nl)
ZA (1) ZA200408342B (nl)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
EP1751144B1 (en) * 2004-05-28 2008-08-27 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
CA2582353A1 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
SG158885A1 (en) * 2005-01-14 2010-02-26 Schering Corp Synthesis of himbacine analogs
MX2007008622A (es) * 2005-01-14 2007-09-11 Schering Corp Una sintesis exo-selectiva de analogos de himbacina.
JP4681616B2 (ja) * 2005-01-14 2011-05-11 シェーリング コーポレイション ヒンバシンアナログのエキソ−およびジアステレオ−選択的合成
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
EP1848683A2 (en) * 2005-01-14 2007-10-31 Schering Corporation Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs
AR053566A1 (es) * 2005-03-31 2007-05-09 Schering Corp Compuestos espiriciclicos antagonistas de los receptores de trombina
US20070219154A1 (en) * 2005-12-20 2007-09-20 Suxing Liu Methods for preventing and/or treating a cell proliferative disorder
JP2009521472A (ja) * 2005-12-22 2009-06-04 シェーリング コーポレイション 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
EP2266976B1 (en) * 2006-04-13 2013-07-31 Merck Sharp & Dohme Corp. Fused ring thrombin receptor antagonists
JP2009542662A (ja) * 2006-06-29 2009-12-03 シェーリング コーポレイション 置換二環系および置換三環系トロンビン受容体アンタゴニスト
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
EP2069326B1 (en) * 2006-10-04 2015-03-18 Merck Sharp & Dohme Corp. Bicyclic and tricyclic derivatives as thrombin receptor antagonists
MX2009003758A (es) * 2006-10-04 2009-04-22 Schering Corp Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina.
US20080194560A1 (en) * 2006-12-22 2008-08-14 Zhi Yun Wang Disintegration promoters in solid dose wet granulation formulations
BRPI0809095A2 (pt) * 2007-03-23 2014-09-09 Schering Corp Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina
CN101981035B (zh) 2008-02-05 2013-08-28 赛诺菲-安万特 作为par1抑制剂的三唑*盐、其制备及其作为药物的用途
AU2009211887B2 (en) 2008-02-05 2013-09-19 Sanofi Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
MX2010012635A (es) 2008-05-19 2010-12-06 Schering Corp Compuestos heterociclicos como inhibidores de factor ixa.
WO2010141525A1 (en) * 2009-06-04 2010-12-09 Schering Corporation Active metabolite of a thrombin receptor antagonist
MX2011013091A (es) 2009-06-08 2012-01-12 Schering Corp Un antagonista del receptor de trombina y tableta con dosificacion fija de clopidogrel.
TWI393716B (zh) 2009-08-04 2013-04-21 Merck Sharp & Dohme 作為ｉｘａ因子抑制劑之雜環化合物
ES2527535T3 (es) 2010-04-16 2015-01-26 Sanofi Piridil-vinil-pirazolo-quinolinas como inhibidores de PAR1
WO2011128421A1 (de) 2010-04-16 2011-10-20 Sanofi Trizyklische pyridyl-vinyl-pyrrole als par1-inhibitoren
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
US9340530B2 (en) 2012-03-06 2016-05-17 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists
WO2015013083A1 (en) * 2013-07-22 2015-01-29 Merck Sharp & Dohme Corp. Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin
US20160200715A1 (en) * 2013-08-22 2016-07-14 Merck Sharp & Dohme Corp. Preparation and use of 7a-heterocycle substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
US9701669B2 (en) 2013-08-22 2017-07-11 Merck Sharp & Dohme Corp. Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
WO2015026686A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
CN107304200B (zh) * 2016-04-22 2021-09-21 江苏天士力帝益药业有限公司 一种新的喜巴辛类似物及其在医药中的应用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
CN116133660A (zh) 2020-07-22 2023-05-16 詹森药业有限公司 可用作因子XIa抑制剂的化合物
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
JP3449620B2 (ja) * 1997-11-25 2003-09-22 シェーリング コーポレイション トロンビンレセプターアンタゴニスト
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
PE20020235A1 (es) 2000-06-15 2002-04-02 Schering Corp Derivados de nor-seco himbacina como antagonistas de los receptores de trombina
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
CA2463628A1 (en) 2001-10-18 2003-04-24 Schering Corporation Himbacine analogues as thrombin receptor antagonists

Also Published As

Publication number Publication date
EP1860106B1 (en) 2010-01-20
ATE378330T1 (de) 2007-11-15
KR20040099441A (ko) 2004-11-26
MY144040A (en) 2011-07-29
EP1982984A2 (en) 2008-10-22
WO2003089428A1 (en) 2003-10-30
AR039570A1 (es) 2005-02-23
IL164585A0 (en) 2005-12-18
NO2015016I1 (no) 2015-07-20
LTC1495018I2 (lt) 2017-04-10
ES2297150T7 (es) 2012-03-16
EP1982984B1 (en) 2013-02-13
CY1107184T1 (el) 2012-10-24
NZ575139A (en) 2010-08-27
HK1129893A1 (en) 2009-12-11
EP1495018A1 (en) 2005-01-12
DK2065384T3 (da) 2011-05-02
SG164279A1 (en) 2010-09-29
PT1495018E (pt) 2008-02-19
KR101026929B1 (ko) 2011-04-04
IL164585A (en) 2010-11-30
US20070179187A1 (en) 2007-08-02
JP4558331B2 (ja) 2010-10-06
MXPA04010308A (es) 2005-02-03
ES2357876T3 (es) 2011-05-03
DE60317493D1 (en) 2011-01-13
EP1495018B1 (en) 2007-11-14
LU92759I2 (en) 2015-08-31
NO2015016I2 (no) 2015-07-09
RU2329264C9 (ru) 2009-04-20
DE60335679D1 (de) 2011-02-17
PE20040412A1 (es) 2004-07-12
ES2297150T3 (es) 2008-05-01
PL214718B1 (pl) 2013-09-30
TW200404068A (en) 2004-03-16
HK1123302A1 (en) 2009-06-12
ZA200408342B (en) 2006-05-31
CY2015029I1 (el) 2016-04-13
FR15C0047I1 (nl) 2015-08-28
AU2003221932B2 (en) 2007-11-22
ATE455774T1 (de) 2010-02-15
BRPI0309309B1 (pt) 2018-09-04
EP1982984A3 (en) 2008-10-29
EP1495018B3 (en) 2011-03-16
NO330500B1 (no) 2011-05-02
JP2005528406A (ja) 2005-09-22
SI2065384T1 (sl) 2011-05-31
EP2062890A1 (en) 2009-05-27
EP1860106A1 (en) 2007-11-28
TWI343919B (en) 2011-06-21
ECSP045368A (es) 2005-01-03
EP2062890B1 (en) 2011-01-05
US7713999B2 (en) 2010-05-11
FR15C0047I2 (fr) 2016-05-06
CN1659162A (zh) 2005-08-24
PT2065384E (pt) 2011-03-16
CA2482858A1 (en) 2003-10-30
DE60331114D1 (de) 2010-03-11
PL373332A1 (en) 2005-08-22
NO20044963L (no) 2004-11-15
US20030216437A1 (en) 2003-11-20
BRPI0309309B8 (pt) 2021-05-25
CY2015029I2 (el) 2016-04-13
RU2329264C2 (ru) 2008-07-20
RU2004133375A (ru) 2005-07-10
DE60317493T2 (de) 2008-09-18
US20070270439A1 (en) 2007-11-22
ATE494284T1 (de) 2011-01-15
CA2482858C (en) 2010-11-30
HK1070887A1 (en) 2005-06-30
RU2008106401A (ru) 2009-08-27
BR0309309A (pt) 2005-02-15
EP2065384B1 (en) 2011-01-05
NZ535880A (en) 2007-11-30
NL300746I1 (nl) 2016-01-21
DK1495018T3 (da) 2008-02-18
EP2065384A1 (en) 2009-06-03
DE60317493T3 (de) 2018-07-12
JP2010132710A (ja) 2010-06-17
SI1495018T1 (sl) 2008-04-30
US7304078B2 (en) 2007-12-04
CY1111363T1 (el) 2015-08-05
CN1659162B (zh) 2011-08-31
ES2338171T3 (es) 2010-05-04
AU2003221932A1 (en) 2003-11-03

Similar Documents

Publication Publication Date Title
BE2019C547I2 (nl)
BE2019C510I2 (nl)
BE2018C021I2 (nl)
BE2017C049I2 (nl)
BE2016C069I2 (nl)
BE2016C040I2 (nl)
BE2016C013I2 (nl)
BE2018C018I2 (nl)
BE2016C002I2 (nl)
BE2015C078I2 (nl)
FR15C0047I1 (nl)
BE2015C017I2 (nl)
BE2014C053I2 (nl)
BE2014C051I2 (nl)
BE2014C041I2 (nl)
BE2014C030I2 (nl)
JP2003222695A5 (nl)
JP2003215004A5 (nl)
BRPI0302144A2 (nl)
BRPI0215435A2 (nl)
JP2003243671A5 (nl)
JP2003199791A5 (nl)
JP2003118312A5 (nl)
JP2003252558A5 (nl)
JP2002319652A5 (nl)